This is GOOD news.CLDX outstanding number of shares is a tiny 32 Million.DNDN's has: 145 Million. The reward of being able to finance the drug on your own will far outweigh the perceived "negative" of increased number of shares which will still be about a 1/4 of DNDN's.
The market for prostate cancer is much, much larger than the markets for glioblastoma that exhibits EGFRviii or triple-negative breast cancer that exhibits GPNMB.
thus the 5 bil mkt cap on DNDN. vs $120mil mkt cap on CLDX
i couldnt agree more. i wish management didnt appear to be so screwed up but i am all in and happy it is behind us. 42mil is tiny for a biotech with our potential
yeah good news when i tell my wife i lost 10 thousand dollars today
Not even close. Impossible to have a logical discussion with idiots or shorts who hope to make few cents on a dilution news. Obviously not all dilution are equal.
what about the NEXT offering, and the NEXT?
new to this board? hmmm.
You will need 10 offerings of 10M each to get to DNDN's number of shares. I suspect we reach the final stage and FDA approval FAR PRIOR to that point. Funny how ignorant public always penalize a Co for ensuring its survival. Survival means that we will make it to the finish line.32 or 45 Million shares is TOTALLY irrelevant. Judging fr DNDN's story of 145 M shares, it is obvious that the final goal is to get to a marketable product.